FDA Advisory Cuts & Biotech Updates: Xenon’s Epilepsy Data & Semaglutide Costs

The biotech landscape is shifting, with developments ranging from evolving regulatory scrutiny of weight-loss drugs to promising clinical trial results for epilepsy treatments. This week’s Readout newsletter from STAT News highlights a notable reduction in public advisory committee meetings at the FDA, raising questions about transparency in drug approvals. Simultaneously, novel analysis suggests that generic versions of semaglutide, a popular drug for diabetes and weight loss, could become significantly more affordable once patents expire. And, in a setback for Roche, their breast cancer drug is facing challenges with the FDA.

FDA Advisory Committee Meetings: A Shifting Landscape

The Food and Drug Administration has been holding fewer public advisory committee meetings, a trend that’s drawing concern from industry leaders, patient advocates, and academic experts. These committees, composed of external experts, traditionally provide independent advice to the FDA on the safety and efficacy of new drugs. Lizzy Lawrence at STAT News reports on the growing unease surrounding this shift, with some fearing it could compromise the rigor of the drug approval process. Readout subscribers can find more details on the specific concerns raised by stakeholders.

Generic Semaglutide: Affordability on the Horizon?

For individuals managing type 2 diabetes or seeking weight loss solutions, the cost of medications like Ozempic and Wegovy (both semaglutide-based) can be substantial. Though, a new analysis suggests a potential pathway to greater affordability. Once patents on these drugs expire, generic semaglutide could be produced for just a few dollars a month. This prospect offers a significant benefit to patients who currently face high out-of-pocket costs. Novo Nordisk gained FDA approval for an oral formulation of Wegovy in December 2025, marking the first oral GLP-1RA specifically for obesity treatment in the US. Yahoo Finance reports that the starting dose of the oral Wegovy will be available for $149 per month, with a maintenance dose of 25mg available by prescription.

Semaglutide belongs to a class of drugs called glucagon-like peptide-1 receptor agonists (GLP-1RAs). These medications work by mimicking the effects of a natural hormone that regulates appetite and blood sugar levels. They can be effective for both weight management and controlling blood glucose in people with type 2 diabetes. The initial approval of oral semaglutide, Rybelsus, was in 2019, but it was specifically for type 2 diabetes. The recent approval of oral Wegovy expands its use to include obesity treatment.

Fraudulent Compounded Semaglutide: A Safety Alert

The FDA has issued warnings about fraudulent compounded versions of semaglutide circulating in the US. The FDA’s alert highlights that these products may contain false information on their labels and pose potential health risks. Compounding pharmacies create customized medications by combining ingredients, but they are not subject to the same rigorous FDA oversight as manufacturers of approved drugs. Patients should only obtain semaglutide from legitimate pharmacies and should be wary of products marketed online with unsubstantiated claims.

Xenon Pharmaceuticals’ Epilepsy Drug: Promising Phase 3 Results

Xenon Pharmaceuticals is reporting encouraging results from a Phase 3 clinical trial of its seizure drug. STAT Plus reports that the drug demonstrated strong efficacy in late-stage trials, potentially offering a new treatment option for individuals with epilepsy. Phase 3 trials are the final stage of clinical testing before a drug can be submitted for FDA approval. The details of the trial, including the specific endpoints and patient population, are available to STAT+ subscribers. The positive results have led to a significant increase in Xenon’s stock price, with a jump of over 48% as of March 9, 2026.

Roche’s Breast Cancer Drug Faces FDA Setback

Roche is experiencing a setback in the development of its breast cancer drug, as reported by STAT News. The FDA has raised concerns regarding the drug, leading to a delay in its potential approval. The specific nature of the FDA’s concerns has not been publicly disclosed, but it represents a challenge for Roche in its efforts to expand its oncology portfolio. This news comes amidst other developments in the biotech sector, including the positive results from Xenon Pharmaceuticals and the anticipated availability of generic semaglutide.

Understanding Clinical Trial Phases

Clinical trials are conducted in several phases to assess the safety and efficacy of new drugs. Phase 1 trials typically involve a small number of healthy volunteers and focus on safety. Phase 2 trials involve a larger group of patients and evaluate the drug’s effectiveness and side effects. Phase 3 trials are the largest and most rigorous, involving hundreds or thousands of patients and comparing the new drug to existing treatments or a placebo. Successful completion of Phase 3 trials is generally required before a drug can be approved by the FDA.

The FDA’s review process involves a thorough evaluation of the clinical trial data, manufacturing processes, and labeling information. The agency may request additional information from the drug manufacturer or convene an advisory committee to provide independent advice. The ultimate decision to approve a drug rests with the FDA.

Looking ahead, the biotech industry will continue to navigate a complex regulatory landscape and strive to develop innovative treatments for a wide range of diseases. The availability of generic semaglutide promises to improve access to affordable medications, whereas ongoing research and clinical trials hold the potential for breakthroughs in areas such as epilepsy and cancer.